Buy these 4 ASX 300 shares, say top brokers

Market analysts have upgraded their ratings on these four ASX 300 shares today.

| More on:
A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

S&P/ASX 300 Index (ASX: XKO) shares are having a belter with the index up 1.46% to 7,058.6 points.

The strong daily gain comes amid new United States inflation data released overnight.

Headline US inflation declined to 3.2% for the 12 months to October, down from 3.7% over the past two months.

Core inflation, which excludes volatile items like energy and food, came in at its lowest level in two years at 4%. These numbers could signal the end of interest rate hikes in the world's biggest economy.

Amid this news, brokers have upgraded the following four ASX 300 shares (courtesy The Australian).

CSL Limited (ASX: CSL)

The CSL share price is currently $259.98, up 2.5% at the time of writing. Top broker Goldman Sachs says the blue-chip ASX 300 biotech share is now at a "compelling entry point after [a] multiple de-rate". It has upgraded CSL to a buy rating with a 12-month share price target of $309, implying a 19% potential upside. Goldman's price target is conservative compared to other top brokers, with the most bullish being UBS, with its target of $340 per share. Ellerston Capital portfolio manager, Chris Kourtis says the CSL share price has been "absolutely pulverised" and is a great buy-the-dip opportunity for investors today.

Clinuvel Pharmaceuticals Limited (ASX: CUV)

The Clinuvel share price is $16.53, up 3.3% so far today. Morgans has commenced coverage of the ASX 300 healthcare share with an add rating and a $22 share price target. If Morgans has it right, investors could be set for a 33% gain in just 12 months. Clinuvel released a new presentation regarding its phase three vitiligo treatment program last Friday.


The ALS share price is $12.03, up 3.8% so far today. Jefferies has upgraded the ASX 300 industrial share to a buy rating with a $13.20 share price target. This implies a potential upside of just under 10%. The testing solutions company reported an underlying net profit after tax (NPAT) of $158 million and a partially franked interim dividend of 19.6 cents per share for the 1H FY24 period yesterday.

Maas Group Holdings Ltd (ASX: MGH)

The Maas Group share price is $3.57, down 0.56% today. Also an ASX 300 industrial share, Maas Group has attracted a buy rating from Jefferies. The broker has commenced coverage with a $4.25 target. This means investors who buy today could enjoy a 19% upside over the next 12 months. CEO and managing director Wes Maas discussed FY24 guidance at the AGM in late October, telling investors the company expected proforma earnings before interest, taxes, depreciation, and amortisation (EBITDA) in the range of $190 million to $210 million.

Motley Fool contributor Bronwyn Allen has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A smiling woman with a satisfied look on her face lies on a rug in her home with her laptop open and a large cup on the floor nearby, gazing at the screen. researching new ETFs
Cheap Shares

'Indiscriminately sold': The ASX shares that are ridiculously cheap right now

The experts at ICE Investors reckon the discounting of these stocks is 'unjustified'.

Read more »

A cute little boy, short in height, wearing glasses, old-fashioned bow tie and cardigan stands against a wall near a tape measure with his hand at the top of his head as though to measure his height.
Broker Notes

Are ASX short sellers right about Pilbara Minerals shares?

Let's see what some of the big brokers think.

Read more »

A woman smiles at the outlook she sees through binoculars.
Investing Strategies

Profit up 24%: 2 classic ASX 200 stocks looking good for 2024

This pair has been a staple for many portfolios in the past, but experts reckon they're representing excellent value for…

Read more »

A woman looks over her shoulder towards the back seat while sitting at the wheel of a stationary car with a serious look on her face.
Cheap Shares

Down 23%, this ASX 200 stock is now ready for 'a turnaround story'

All companies encounter difficult periods, but if it's temporary then it's time for shrewd investors to swoop.

Read more »

A female executive smiles as she carries out business on her mobile phone.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Three satisfied miners with their arms crossed looking at the camera proudly
Resources Shares

Lithium, copper and gold stocks: Will they GO OFF IN 2024?

Bell Direct's Grady Wulff analyses the three hottest commodities to determine what their fortunes could be like next year.

Read more »

A group of people crowd around a guy sitting at a computer, and two plant kisses on his cheeks, the rest cheering.
Investing Strategies

2 'out of favour' ASX 200 shares that could make you serious money

DNR Capital's Jamie Nicol reveals there are 2 types of stocks you should buy right now.

Read more »

two men smiling with a laptop in front of them, symbolising a rising share price.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave the thumbs up to these ASX shares last week. Why are they bullish?

Read more »